Target family: Cannabinoid receptors (type: gpcr)
Target: CB<sub>2</sub> receptor

Ligand: 2-arachidonoylglycerol (Metabolite)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
Published in: Biochem Pharmacol

Ligand: 2-arachidonoylglycerol (Metabolite)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity.
Published in: Eur J Pharmacol

Ligand: AM10257 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.119999885559082 pKi
Reference (Journal): Crystal Structure of the Human Cannabinoid Receptor CB2.
Published in: Cell

Ligand: AM1241 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pKi
Reference (Journal): In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?
Published in: Br J Pharmacol

Ligand: AM1710 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.170000076293945 pKi
Reference (Journal): Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
Published in: J Med Chem

Ligand: AM2201 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.59000015258789 pKi
Reference (Patent): Cannabimimetic indole derivatives

Ligand: AM2201 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.230000019073486 pEC50
Reference (Journal): Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135.
Published in: ACS Chem Neurosci

Ligand: AM-630 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.5 pKi
Reference (Journal): Agonist-inverse agonist characterization at CB<sub>1</sub> and CB<sub>2</sub> cannabinoid receptors of L759633, L759656 and AM630.
Published in: Br J Pharmacol

Ligand: AM7499 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 10 pKi
Reference (Journal): Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues.
Published in: J Med Chem

Ligand: AM7499 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.510000228881836 pKi
Reference (Journal): Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues.
Published in: J Med Chem

Ligand: anandamide (Metabolite)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
Published in: Biochem Pharmacol

Ligand: anandamide (Metabolite)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Published in: Mol Pharmacol

Ligand: anandamide (Metabolite)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Published in: J Pharmacol Exp Ther

Ligand: AZD1940 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.0600004196167 pKi
Reference (Journal): Benzo[d]thiazol-2(3H)-ones as new potent selective CB<sub>2</sub> agonists with anti-inflammatory properties.
Published in: Eur J Med Chem

Ligand: BAY-593074 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 7.340000152587891 pKi
Reference (Journal): 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
Published in: J Pharmacol Exp Ther

Ligand: BMS-202 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.880000114440918 pEC50
Reference (Journal): Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135.
Published in: ACS Chem Neurosci

Ligand: cannabinor (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.869999885559082 pKi
Reference (Journal): Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats.
Published in: Eur Urol

Ligand: cannabinor (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.760000228881836 pEC50
Reference (Journal): Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats.
Published in: Eur Urol

Ligand: cannabinor (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pKi
Reference (Journal): Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats.
Published in: Eur Urol

Ligand: compound C2 [PMID: 29990428] (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Identification of the First Synthetic Allosteric Modulator of the CB<sub>2</sub> Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief.
Published in: J Med Chem

Ligand: CP55940 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Agonist-inverse agonist characterization at CB<sub>1</sub> and CB<sub>2</sub> cannabinoid receptors of L759633, L759656 and AM630.
Published in: Br J Pharmacol

Ligand: CP55940 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Published in: J Pharmacol Exp Ther

Ligand: CP55940 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Published in: Mol Pharmacol

Ligand: Δ9-tetrahydrocannabinol (Natural product)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: no
Median affinity:  pKi
Reference (Journal): Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Published in: Mol Pharmacol

Ligand: Δ9-tetrahydrocannabinol (Natural product)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: no
Median affinity:  pKi
Reference (Journal): Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Published in: J Pharmacol Exp Ther

Ligand: Δ9-tetrahydrocannabinol (Natural product)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: no
Median affinity:  pKi
Reference (Journal): Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
Published in: J Med Chem

Ligand: (E)-beta-caryophyllene (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.71999979019165 pEC50
Reference (Journal): Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus.
Published in: Eur J Med Chem

Ligand: GW405833 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6.96999979019165 pEC50
Reference (Journal): Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.
Published in: Br J Pharmacol

Ligand: GW842166 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.039999961853027 pEC50
Reference (Journal): The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.
Published in: Bioorg Med Chem Lett

Ligand: GW842166 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.199999809265137 pEC50
Reference (Journal): The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.
Published in: Bioorg Med Chem Lett

Ligand: HU-210 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Published in: Mol Pharmacol

Ligand: HU-210 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Published in: J Pharmacol Exp Ther

Ligand: HU-210 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
Published in: J Med Chem

Ligand: ibipinabant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.099999904632568 pKi
Reference (Journal): Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
Published in: J Med Chem

Ligand: JWH-018 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.5 pKi
Reference (Journal): The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor.
Published in: J Pharmacol Exp Ther

Ligand: JWH-133 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.5 pKi
Reference (Journal): 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor.
Published in: Bioorg Med Chem

Ligand: JWH-133 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.5 pKi
Reference (Journal): Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development.
Published in: Expert Opin Investig Drugs

Ligand: L-759,633 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors.
Published in: Bioorg Med Chem Lett

Ligand: L-759,633 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Agonist-inverse agonist characterization at CB<sub>1</sub> and CB<sub>2</sub> cannabinoid receptors of L759633, L759656 and AM630.
Published in: Br J Pharmacol

Ligand: L-759,656 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Agonist-inverse agonist characterization at CB<sub>1</sub> and CB<sub>2</sub> cannabinoid receptors of L759633, L759656 and AM630.
Published in: Br J Pharmacol

Ligand: L-759,656 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors.
Published in: Bioorg Med Chem Lett

Ligand: lenabasum (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.769999980926514 pKi
Reference (Journal): Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
Published in: J Med Chem

Ligand: lenabasum (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.769999980926514 pKi
Reference (Journal): Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Published in: J Med Chem

Ligand: LY2828360 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.440000057220459 pKi
Reference (Journal): Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.
Published in: J Med Chem

Ligand: LY2828360 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pEC50
Reference (Journal): Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.
Published in: J Med Chem

Ligand: LY2828360 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.389999866485596 pKi
Reference (Journal): Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.
Published in: J Med Chem

Ligand: MDMB-Fubinaca (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.890000343322754 pKi
Reference (Journal): Pharmacological evaluation of new constituents of &quot;Spice&quot;: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds.
Published in: Forensic Toxicol

Ligand: nabilone (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: no
Median affinity: 8.199999809265137 pKi
Reference (Journal): Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
Published in: Eur J Med Chem

Ligand: olorinab (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: yes
Median affinity: 8.210000038146973 pEC50
Reference (Journal): Discovery of APD371: Identification of a Highly Potent and Selective CB<sub>2</sub> Agonist for the Treatment of Chronic Pain.
Published in: ACS Med Chem Lett